文献速递消化系统肿瘤泌尿男性生殖肿瘤乳腺癌

FGFR抑制剂疗效因基因改变类型而异:单中心真实世界回顾性队列

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.
PubMed 文献 · Eur J Cancer · 2026-06-19

该单中心回顾性队列纳入158例接受FGFR抑制剂治疗的FGFR改变患者,按改变类型分析结局。FGFR融合(多见于胆管癌)疗效最佳,ORR 45.9%,中位PFS 7.3个月、OS 19.7个月;FGFR扩增(多见于乳腺癌)疗效最差,ORR 11.1%,中位PFS 2.1个月、OS 9.9个月;FGFR突变(多见于尿路上皮癌)疗效居中。再次使用FGFR抑制剂疗效劣于首次暴露。

要点

  • FGFR融合患者ORR 45.9%,中位PFS 7.3个月、OS 19.7个月,获益最显著。
  • FGFR扩增患者ORR 11.1%,中位PFS 2.1个月、OS 9.9个月,疗效最差。
  • 再次FGFR抑制剂ORR 13.6% vs 首次47.6%,中位PFS 3.8 vs 8.5个月。

核心结论

  • FGFR抑制剂的临床活性在FGFR改变类型和肿瘤类型间存在异质性。
  • FGFR融合和突变与更大获益相关,而FGFR扩增未显示获益。

研究设计与样本

  • 单中心回顾性队列研究,纳入2011年2月至2025年3月在Gustave Roussy接受FGFR抑制剂治疗的多项临床试验和常规诊疗患者。
  • 共158例FGFR改变患者,其中FGFR扩增27例、FGFR融合76例、FGFR突变55例。

主要发现

  • FGFR融合最常见于胆管癌,ORR 45.9%,中位PFS 7.3个月,中位OS 19.7个月。
  • FGFR扩增主要见于乳腺癌,ORR 11.1%,中位PFS 2.1个月,中位OS 9.9个月。
  • FGFR突变主要见于尿路上皮癌,ORR 30.9%,中位PFS 4.7个月,中位OS 12.4个月。
  • 22例接受第二种FGFR抑制剂的患者,ORR 13.6% vs 首次47.6%,中位PFS 3.8 vs 8.5个月。

临床怎么用

  • FGFR融合或突变患者可能从FGFR抑制剂中获得更大获益,扩增患者获益有限。
  • 再次使用FGFR抑制剂疗效下降,需考虑耐药机制并探索下一代FGFR抑制剂。

局限性

  • 单中心回顾性研究,样本量有限,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibroblast growth factor receptor (FGFR) alterations including mutations, fusions and amplifications, are known oncogenic drivers. FGFR tyrosine kinase inhibitors (FGFRi) have demonstrated clinical activity in patients with FGFR3-driven urothelial carcinoma and FGFR2-driven cholangiocarcinoma. This study aims to describe outcomes with FGFRi according to alteration and tumor type. METHODS: We retrospectively assessed data from patients with FGFR alterations treated by an FGFRi in multiple clinical trials and in routine care at Gustave Roussy. RESULTS: Among 158 patients treated by an FGFRi from February 2011 to March 2025, 27 had FGFR amplifications, 76 FGFR fusions, and 55 FGFR mutations. FGFR fusions, most common in cholangiocarcinoma, were associated with the most favorable outcomes with an overall response rate (ORR) of 45.9%, median progression free survival (PFS) and overall survival (OS) of 7.3 and 19.7 months, respectively. FGFR amplifications, found predominantly in breast cancer, were associated with the poorest outcomes (ORR of 11.1%, median PFS and OS of 2.1 and 9.9 months, respectively). FGFR mutations, observed mainly in urothelial carcinoma, showed intermediate efficacy (ORR of 30.9%, median PFS and OS of 4.7 and 12.4 months, respectively). Among the 22 patients who received a second FGFRi, outcomes were inferior to firsts exposure (ORR of 13.6% vs 47.6% and median PFS of 3.8 vs 8.5 months). CONCLUSION: Clinical activity of FGFRi was heterogenous across FGFR alteration and tumor types. FGFR fusions and mutations were associated with greater benefit, whereas amplifications were not. Further investigation of resistance mechanisms and development of next-generation FGFRi are needed.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pobel C, Badreddine H, Smolenschi C, et al. Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort. Eur J Cancer. 2026. PMID: 42330567. doi:10.1016/j.ejca.2026.116900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。